Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.62 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.61 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.56 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.50 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.49 |
| ▸ | GLP1R | P43220 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20543076 | 1.00 | LPAR3 (0.62) | LPAR3LPAR1CAPN1PLA2G10MMP8 | |
| SCHEMBL20543074 | 1.00 | LPAR3 (0.62) | LPAR3LPAR1CAPN1PLA2G10MMP8 | |
| SCHEMBL20542955 | 1.00 | LPAR3 (0.62) | LPAR3LPAR1CAPN1PLA2G10MMP8 | |
| SCHEMBL20543024 | 1.00 | LPAR3 (0.62) | LPAR3LPAR1CAPN1PLA2G10MMP8 | |
| SCHEMBL20542957 | 1.00 | LPAR3 (0.62) | LPAR3LPAR1CAPN1PLA2G10MMP8 | |
| SCHEMBL20542713 | 1.00 | LPAR3 (0.62) | LPAR3LPAR1CAPN1PLA2G10MMP8 | |
| SCHEMBL20543107 | 1.00 | LPAR3 (0.62) | LPAR3LPAR1CAPN1PLA2G10MMP8 | |
| SCHEMBL20542711 | 1.00 | LPAR3 (0.62) | LPAR3LPAR1CAPN1PLA2G10MMP8 | |
| SCHEMBL20542958 | 1.00 | LPAR3 (0.62) | LPAR3LPAR1CAPN1PLA2G10MMP8 | |
| SCHEMBL20543021 | 1.00 | LPAR3 (0.62) | LPAR3LPAR1CAPN1PLA2G10MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180311342-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-11-01 | — | — | US | claimed |
| EP-3395365-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-10-31 | — | — | EP | claimed |
| US-20180311342-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-11-01 | — | — | US | disclosed |
| EP-3395365-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180311342-A1 | IMMUNOSTIMULATING AGENT | MYD88, TLR9, IL2 | LPAR3 1610/4885LPAR1 579/4885CAPN1 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.